What's going on with African swine fever vaccine candidates? Will pork prices continue to rise? According to the report of voice of China, Chinese scientists have created a candidate vaccine for African classical swine fever, which has achieved phased results. Laboratory research results show that it has good biological safety and immune protection effect, and will accelerate the promotion of pilot and clinical trials.
It is reported that five major advances have been made in the development of African classical swine fever vaccine
One is to isolate the first African classical swine fever virus in China. The virus cell isolation and culture system and animal infection model were established, and the biological characteristics such as infectivity, pathogenicity and transmission ability were systematically studied. The genomic characteristics and evolutionary relationship of African classical swine fever epidemic strains in China were revealed.
The second is the creation of African classical swine fever candidate vaccine. Laboratory studies have proved that two candidate vaccine strains have good biological safety and immune protection effect.
Third, the two candidate vaccine strains have strong genetic stability in vitro and in vivo. The biological characteristics and genomic sequence of the two candidate vaccine strains were not significantly changed after continuous passage in primary cells in vitro, and the virulence of the two candidate vaccine strains was not significantly increased after continuous passage in pigs.
Fourth, the minimum protective dose was defined to prove the safety of large dose and repeated dose.
Fifthly, preclinical pilot product technology research has been preliminarily completed. At present, the production seed bank of two candidate vaccines has been established, the purity and exogenous virus test of vaccine production seed batch has been preliminarily completed, and the cell culture and freeze-drying process of candidate vaccines have been preliminarily optimized.
Next, on the basis of the research progress in vaccine laboratory stage, CAAS will accelerate the pilot and clinical trials, as well as the research work of vaccine production, and complete the research work of immune mechanism, diagnostic detection, disinfection and pest control technology as soon as possible, so as to provide timely, effective and powerful scientific and technological support for the national and industrial needs.